Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1361970-55-9

Post Buying Request

1361970-55-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1361970-55-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1361970-55-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,9,7 and 0 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1361970-55:
(9*1)+(8*3)+(7*6)+(6*1)+(5*9)+(4*7)+(3*0)+(2*5)+(1*5)=169
169 % 10 = 9
So 1361970-55-9 is a valid CAS Registry Number.

1361970-55-9Relevant articles and documents

Development of Flexible and Scalable Routes to Two Phosphatidinylinositol-3-kinase Delta Inhibitors via a Common Intermediate Approach

Edney, Dean,Hulcoop, David G.,Leahy, John H.,Vernon, Lois E.,Wipperman, Mark D.,Bream, Robert N.,Webb, Michael R.

, p. 368 - 376 (2018/03/22)

This paper describes the discovery and development of a flexible route to two candidate drug molecules by a common intermediate approach. Key reactions include Negishi and Suzuki couplings to form biaryl bonds. Conditions for a Miyaura borylation of heteroaryl bromides were also developed. Heteroaryl trifluoroborates and aryl chlorides were used as coupling partners in the Suzuki reaction, thereby minimizing detrimental side reactions such as protodeboronation and oxidative homocoupling. A complementary set of reaction conditions using pinacolboronates with potassium bifluoride as an additive were also developed and used to make 5 kg of drug substance for use in early-phase clinical trials.

Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

Down, Kenneth,Amour, Augustin,Baldwin, Ian R.,Cooper, Anthony W.J.,Deakin, Angela M.,Felton, Leigh M.,Guntrip, Stephen B.,Hardy, Charlotte,Harrison, Zo? A.,Jones, Katherine L.,Jones, Paul,Keeling, Suzanne E.,Le, Joelle,Livia, Stefano,Lucas, Fiona,Lunniss, Christopher J.,Parr, Nigel J.,Robinson, Ed,Rowland, Paul,Smith, Sarah,Thomas, Daniel A.,Vitulli, Giovanni,Washio, Yoshiaki,Hamblin, J. Nicole

, p. 7381 - 7399 (2015/10/05)

Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (GSK2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1361970-55-9